Search Result

Results for "

cyclin+D1

" in MedChemExpress (MCE) Product Catalog:

標的別:	CDK (62) Cyclin G-associated Kinase (GAK) (1) 5-HT Receptor (1) ADAMTS (1) Adrenergic Receptor (6) Akt (10) Androgen Receptor (1) AP-1 (1) Apoptosis (49) Atg7 (1) Atg8/LC3 (2) Aurora Kinase (2) Autophagy (13) Bacterial (2) Bcl-2 Family (15) Biochemical Assay Reagents (1) BMX Kinase (1) c-Met/HGFR (1) c-Myc (11) Cadherin (2) Casein Kinase (1) Caspase (11) Checkpoint Kinase (Chk) (1) CXCR (3) Deubiquitinase (3) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (1) EGFR (3) Endogenous Metabolite (3) ERK (8) Estrogen Receptor/ERR (1) Eukaryotic Initiation Factor (eIF) (3) Farnesyl Transferase (2) FLT3 (3) Fungal (2) FXR (2) GSK-3 (11) HDAC (2) Histamine Receptor (1) HIV (3) HSP (4) IFNAR (1) IKK (2) Interleukin Related (1) Isotope-Labeled Compounds (2) JAK (2) JNK (4) Keap1-Nrf2 (2) Ligands for Target Protein for PROTAC (1) Lipase (1) MDM-2/p53 (5) MEK (5) MicroRNA (1) MMP (3) MNK (1) mTOR (2) NF-κB (8) NO Synthase (1) P-glycoprotein (1) p38 MAPK (5) PAK (2) Parasite (3) PARP (6) Phosphatase (2) Phosphodiesterase (PDE) (1) PI3K (7) PIN1 (1) PINK1/Parkin (1) PKC (3) PPAR (4) PROTACs (1) Raf (2) Ras (1) Reactive Oxygen Species (ROS) (9) Reference Standards (14) SHP1 (1) Sirtuin (1) STAT (13) Stearoyl-CoA Desaturase (SCD) (1) Survivin (3) TGF-beta/Smad (1) TGF-β Receptor (1) Thrombopoietin Receptor (2) TNF Receptor (2) Trk Receptor (1) VEGFR (2) Wnt (7) β-catenin (9)
研究分野別:	Cancer (107) Cardiovascular Disease (8) Endocrinology (1) Infection (11) Inflammation/Immunology (17) Metabolic Disease (4) Neurological Disease (11)

標的別:

CDK (62)

Cyclin G-associated Kinase (GAK) (1)

5-HT Receptor (1)

ADAMTS (1)

Adrenergic Receptor (6)

Akt (10)

Androgen Receptor (1)

AP-1 (1)

Apoptosis (49)

Atg7 (1)

Atg8/LC3 (2)

Aurora Kinase (2)

Autophagy (13)

Bacterial (2)

Bcl-2 Family (15)

Biochemical Assay Reagents (1)

BMX Kinase (1)

c-Met/HGFR (1)

c-Myc (11)

Cadherin (2)

Casein Kinase (1)

Caspase (11)

Checkpoint Kinase (Chk) (1)

CXCR (3)

Deubiquitinase (3)

DNA/RNA Synthesis (1)

Drug Derivative (1)

Drug Intermediate (1)

Drug Metabolite (1)

EGFR (3)

Endogenous Metabolite (3)

ERK (8)

Estrogen Receptor/ERR (1)

Eukaryotic Initiation Factor (eIF) (3)

Farnesyl Transferase (2)

FLT3 (3)

Fungal (2)

FXR (2)

GSK-3 (11)

HDAC (2)

Histamine Receptor (1)

HIV (3)

HSP (4)

IFNAR (1)

IKK (2)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

JAK (2)

JNK (4)

Keap1-Nrf2 (2)

Ligands for Target Protein for PROTAC (1)

Lipase (1)

MDM-2/p53 (5)

MEK (5)

MicroRNA (1)

MMP (3)

MNK (1)

mTOR (2)

NF-κB (8)

NO Synthase (1)

P-glycoprotein (1)

p38 MAPK (5)

PAK (2)

Parasite (3)

PARP (6)

Phosphatase (2)

Phosphodiesterase (PDE) (1)

PI3K (7)

PIN1 (1)

PINK1/Parkin (1)

PKC (3)

PPAR (4)

PROTACs (1)

Raf (2)

Ras (1)

Reactive Oxygen Species (ROS) (9)

Reference Standards (14)

SHP1 (1)

Sirtuin (1)

STAT (13)

Stearoyl-CoA Desaturase (SCD) (1)

Survivin (3)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Thrombopoietin Receptor (2)

TNF Receptor (2)

Trk Receptor (1)

VEGFR (2)

Wnt (7)

β-catenin (9)

研究分野別:

Cancer (107)

Cardiovascular Disease (8)

Endocrinology (1)

Infection (11)

Inflammation/Immunology (17)

Metabolic Disease (4)

Neurological Disease (11)

119

阻害剤およびアゴニスト

ペプチド

阻害性抗体

天然物

組換えタンパク質

同位体標識化合物

抗体

Guggulsterone Maximum Cited Publications 21 Publications Verification Z/E-Guggulsterone	Apoptosis JNK Akt Caspase FXR Autophagy	Cancer
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, *xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1* and c-Myc), activation of caspases and JNK, inhibition of Akt ^[1] . Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC₅₀s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively .

Arctiin 5 Publications Verification Arctii; NSC 315527; Arctigenin-4-glucoside	NF-κB	Inflammation/Immunology Cancer
Arctiin is an orally active inhibitor of NF-κB. Arctiin suppresses cyclin D1 protein expression in human tumor cells. Arctiin also reduces malondialdehyde and pro-in ammatory cytokines levels. Arctiin can used in study glomerulonephritis .

ML364 20+ Cited Publications	Deubiquitinase	Cancer
ML364 is a selective ubiquitin specific peptidase 2 (USP2) inhibitor (IC₅₀=1.1 μM) with anti-proliferative activity, which direct binds to USP2 (K_d=5.2 μM), induces an increase in cellular cyclin D1 degradation and causes cell cycle arrest. ML364 increases the levels of mitochondrial ROS and decreases in the intracellular content of ATP ^[1] .

Obatoclax Mesylate 10+ Cited Publications GX15-070 Mesylate	Bcl-2 Family Autophagy Parasite	Infection Cancer
Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a K_i of 220 nM for BCL-2 ^[1] . Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity .

Milciclib 5+ Cited Publications PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

Lerociclib 2 Publications Verification G1T38	CDK	Cancer
Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC₅₀s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

Decursin 2 Publications Verification (+)-Decursin	PKC Apoptosis CXCR	Neurological Disease Inflammation/Immunology Cancer
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities ^[1] .

Resibufogenin 5+ Cited Publications Bufogenin; Recibufogenin	PI3K Akt NF-κB AP-1 GSK-3 CDK	Neurological Disease Inflammation/Immunology Cancer
Resibufogenin is an orally active anticancer agent. Resibufogenin can be extracted from toad venom. Resibufogenin blocks signaling pathways such as PI3K/Akt, NF-κB, *AP-1, activates GSK-3β, and regulates cyclin D1*. Resibufogenin can activate central neurons. Resibufogenin has anti-inflammatory activity. Resibufogenin has anti-tumor effects on a variety of tumors such as multiple myeloma, renal cancer, colorectal cancer, pancreatic cancer, and glioma ^[1] .

R547 2 Publications Verification	CDK GSK-3 Apoptosis	Cancer
R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively ^[1] .

Purvalanol A 4 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of **cyclin T1-CDK9, cyclin B1-CDK1*, cyclin* E-CDK2, *cyclin D1-CDK4, cyclin* E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

FN-1501 2 Publications Verification LT-171-861	CDK FLT3	Cancer
FN-1501 is a potent inhibitor of FLT3 and CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.

DIF-3 5+ Cited Publications	Wnt CDK GSK-3	Infection Cancer
DIF-3 is an orally active anticancer agent. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in cells. DIF-3 induces reactive oxygen species (ROS) and autophagy. DIF suppresses the growth of Trypanosoma. cruzi in HT1080 cells. DIF-3 exerts antitumor effects both in vitro and in vivo ^[1] .

RGB-286638 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of **cyclin T1-CDK9, cyclin B1-CDK1*, cyclin* E-CDK2, *cyclin D1-CDK4, cyclin* E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

Garcinone D 4 Publications Verification	STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)	Neurological Disease
Garcinone D is an activator of the **STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of CDK2/CyclinE1** (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer ^[1] .

Arcyriaflavin A	Fungal	Cancer
Arcyriaflavin A is an indolo[2,3-a]carbazole compound and also a *cyclin D1/CDK4* inhibitor. Arcyriaflavin A exists in the marine ascidian Eudistoma sp. and the slime mold Arcyria denudata. Arcyriaflavin A is applicable to research related to colon cancer and lung cancer ^[1] .

Riviciclib hydrochloride 3 Publications Verification P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits *CDK9-cyclinT1, *CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀**s of 20 nM, 63 nM, and 79 nM, respectively ^[1] . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .

Briciclib ON 014185	Eukaryotic Initiation Factor (eIF) CDK c-Myc MDM-2/p53 Caspase Apoptosis	Cancer
Briciclib (ON 014185) is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib reduces the expression of *cyclin D1* and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib can be used for the study of hematological system tumors and solid tumors ^[1].

Eurycomalactone	NF-κB Apoptosis Akt Bcl-2 Family	Infection Inflammation/Immunology
Eurycomalactone is an active quassinoid could be isolated from Eurycoma longifolia Jack. Eurycomalactone is a potent NF-κB inhibitor with an IC₅₀ value of 0.5 μM. Eurycomalactone inhibits protein synthesis and depletes cyclin D1. Eurycomalactone enhances radiosensitivity through arrest cell cycle at G2/M phase and delayed DNA double-strand break repair. Eurycomalactone inhibits the activation of AKT/NF-κB signaling, induces apoptosis and enhances chemosensitivity to Cisplatin (HY-17394) ^[1] .

Gomisin G 2 Publications Verification	HIV	Infection
Gomisin G is a lignin from S. chinesis with anti-HIV (EC₅₀ = 0.006 μg/mL), anti-liver cancer and anti-inflammatory activities. Gomisin G has an AKT-cyclin D1 dependent mechanism against triple-negative breast cancer (TNBC) cells through suppressing phosphorylation rather than inducing apoptosis. Gomisin G can inhibit AKT phosphorylation. Gomisin G can cause cell cycle arrest in the G1 phase. Gomisin G can be studied in research for diseases such as HIV, breast and liver cancers ^[1] .

(S)-(−)-Perillyl alcohol	Farnesyl Transferase Apoptosis Endogenous Metabolite	Cancer
(S)-(-)-Perillyl alcohol, a monoterpene, is an orally active farnesyl transferase and geranylgeranyl transferase inhibitor. (S)-(-)-Perillyl alcohol up-regulates the mannose-6-phosphate receptor, facilitating *TGF-β1* activation and cytostasis,. (S)-(-)-Perillyl alcohol induces apoptosis in cancer cells, modulates *cyclin D1* and *AP-1* activity. (S)-(-)-Perillyl alcohol exhibits antitumor activity against sarcoma tumors in mice. (S)-(-)-Perillyl alcohol can be used for the research of squamous cell carcinoma of the esophagus and sarcoma 180 ^[1] .

6:2 Fluorotelomer alcohol 6:2 FTOH; 1H,1H,2H,2H-Perfluoro-1-octanol; 2-(Perfluorohexyl)ethanol	Bacterial Apoptosis ERK TNF Receptor	Infection Neurological Disease
6:2 Fluorotelomer alcohol (6:2 FTOH) is an orally active, blood-brain barrier-permeable modulator of *cyclin D1* and *ETS1. 6:2 Fluorotelomer alcohol downregulates cyclin D1* expression, upregulates *ETS1* via the TNF-α/ERK 1/2 pathway, impairs mitochondrial membrane potential and respiratory function, increases reactive oxygen species levels, disrupts calcium homeostasis and activates endoplasmic reticulum stress markers, and induces cell proliferation inhibition and endothelial-mesenchymal transition. Furthermore, 6:2 Fluorotelomer alcohol induces morphological abnormalities in zebrafish embryos and liver developmental damage, while disrupting the brain immune microenvironment in mice, causing systemic toxicity and delayed pup maturation in CD-1 mice. 6:2 Fluorotelomer alcohol also induces cortical neuron apoptosis, glial cell activation, synaptic abnormalities, colonic barrier damage, intestinal dysbiosis and autism spectrum disorder-like symptoms in mice. 6:2 Fluorotelomer alcohol shows no mutagenic, clastogenic, primary skin/eye irritation or skin sensitizing effects, exhibits no selective reproductive toxicity in CD-1 mice, and is classified as GHS Category 4 for acute oral toxicity. 6:2 Fluorotelomer alcohol can be used in studies of neurodevelopmental disorders and autism spectrum disorders ^[1] .

ON-013100 2 Publications Verification	CDK	Cancer
ON-013100, an antineoplastic agent, acts a mitotic inhibitor that could inhibit *Cyclin D1* expression.

CGP-82996 CINK4	CDK	Cancer
GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC₅₀s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer ^[1] .

Dehydrozingerone	Bacterial Fungal HIV CDK	Infection Cancer
Dehydrozingerone is a ginger-derived component and *cyclin D1* inhibitor that downregulates cyclin D1 expression and induces cell cycle G₁ phase arrest. Dehydrozingerone reduces the proliferative capacity of castration-resistant prostate cancer cells under in vitro conditions. Dehydrozingerone reduces subcutaneous tumor growth by inhibiting cell proliferation and angiogenesis. Dehydrozingerone exerts antibacterial and antifungal activities via its α,β-unsaturated carbonyl conjugated system. Dehydrozingerone can be used in studies related to castration-resistant prostate cancer, bacterial infections, and food spoilage fungal infections ^[1] .

LCH-7749944 5 Publications Verification GNF-PF-2356	PAK Apoptosis	Cancer
LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC₅₀ of 14.93 μM. LCH-7749944 effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclin D1 pathway and induces apoptosis ^[1].

Sulindac sulfone	mTOR Drug Metabolite CDK PPAR Apoptosis	Cancer
Sulindac sulfone is an orally active metabolite of Sulindac (HY-B0008). Sulindac sulfone activates PPARγ and drives transcriptional induction of SSAT by binding to the PPRE-2 element. Sulindac sulfone induces Apoptosis. Sulindac sulfone negatively regulates the function of *VDAC1/2* to inhibit the *mTORC1* pathway, reduces *Cyclin D1* levels, and induces G₁ cell cycle arrest in colon cancer cells. Sulindac sulfone exerts colon cancer preventive effects through a COX-independent mechanism. Sulindac sulfone can be used in research related to colon cancer ^[1] .

Lerociclib dihydrochloride 2 Publications Verification G1T38 dihydrochloride	CDK	Cancer
Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC₅₀s of 1 nM and 2 nM for *CDK4/CyclinD1* and *CDK6/CyclinD3*, respectively.

DK419	Wnt β-catenin c-Myc CDK Survivin	Cancer
DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC₅₀ of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK ^[1].

Obatoclax 10+ Cited Publications GX15-070	Bcl-2 Family Autophagy Parasite	Infection Cancer
Obatoclax (GX15-070), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a K_i of 220 nM for BCL-2 ^[1] . Obatoclax induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax has anti-cancer and broad-spectrum antiparasitic activity .

LCAHA 1 Publications Verification LCA hydroxyamide	Deubiquitinase	Cancer
LCAHA (LCA hydroxyamide) is a deubiquitinase USP2a inhibitor with IC₅₀s of 9.7 μM and 3.7μM in Ub-AMC Assay and Di-Ub Assay, respectively. LCAHA destabilizes Cyclin D1 and induces G0/G1 arrest by inhibiting deubiquitinase USP2a ^[1].

CCT036477	Wnt β-catenin PPAR CDK	Cancer
CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2) ^[1] .

CDK4-IN-1	CDK	Cancer
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.

(-)-Hinesol Hinesol	Apoptosis	Cancer
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer ^[1].

2,5-Dimethylcelecoxib	Wnt Survivin β-catenin	Cancer
2,5-Dimethylcelecoxib is an analogue of celecoxib (HY-14398) with anticancer activity but without COX-2 inhibitory activity. 2,5-Dimethylcelecoxib exerts its anti-cancer cell proliferation effect by inhibiting the core mechanism of the Wnt/β-catenin signaling pathway. 2,5-Dimethylcelecoxib also inhibits T-cell factor-dependent transcriptional activity and inhibits expression of the Wnt/β-catenin target gene products cyclin D1 and survivin ^[1].

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both cdk4 and cdk6 and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase ^[1].

Mabuterol	Adrenergic Receptor	Cardiovascular Disease
Mabuterol is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB ^[1] .

β-catenin-IN-4	β-catenin CDK c-Myc	Cancer
β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a K_i of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc ^[1].

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective CDK4/6 inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research ^[1].

ZSNI-21	HDAC ADAMTS Apoptosis Bcl-2 Family Cyclin G-associated Kinase (GAK)	Cancer
ZSNI-21 is a ADAM17/HDAC2 inhibitor with ADAM17 IC₅₀ 0.939 μM and HDAC2 IC₅₀ 0.844 μM. ZSNI-21 regulates the expression of apoptosis-related proteins (Bax, Bcl-2) and *Cyclin D1*, and induces apoptosis.. ZSNI-21 can be used for the research of hepatocellular carcinoma, breast cancer, and non-small cell lung cancer ^[1].

SR-1277	Casein Kinase	Cancer
SR-1277 is a potent, selective and ATP competitive *CK1δ/ε* inhibitor, with IC₅₀s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, **CDK4/cyclin D1*, CDK6/cyclin* D3 and CDK9/cyclin K, with IC₅₀s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer ^[1].

LLL3 1 Publications Verification CLT-005	STAT Apoptosis	Cancer
LLL3 (CLT-005) is a STAT3 inhibitor. LLL3 inhibits dimerization and phosphorylation of STAT3, thereby preventing intraconuclear transfer of STAT3 and inhibits the expression of STAT3 dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of STAT3 persistent activation types of cancer ^[1] .

Autophagy agonist-1	Autophagy CDK Atg8/LC3 PINK1/Parkin	Cancer
Autophagy agonist-1 (compound 22) is an Autophagy agonist. Autophagy agonist-1 exhibits significant anticancer activity against HepG2 cells and normal cells with IC₅₀s of 8.8 μM and > 50 μM. Autophagy agonist-1 induces G1/S phase cell cycle arrest and inhibits CDK4 and CyclinD1 expression while upregulating P21. Autophagy agonist-1 promotes the accumulation of autophagosomes and the proteins LC3 and *PINK1*, enhancing autophagy and mitophagy in HepG2 cells ^[1].

NSC 625987 1 Publications Verification	CDK	Cancer
NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC₅₀ of 0.2 μM for **CDK4:cyclin D1**. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 ^[1].

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits *CDK9-cyclinT1, *CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀**s of 20 nM, 63 nM, and 79 nM, respectively ^[1] . Riviciclib shows antitumor activity on cisplatin-resistant cells .

Olomoucine II	CDK	Cancer
Olomoucine II is a potent CDK inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity ^[1].

製品番号	製品名	Target	研究分野

HY-P1109

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both cdk4 and cdk6 and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase ^[1].

HY-113770

Lysyl threonine Lys-Thr	Drug Intermediate	Cancer
Lysyl threonine (Lys-Thr) is a dipeptide. Lysyl threonine can be used to synthesize the pentapeptide Gly-Thr-Gly-Lys-Thr. Gly-Thr-Gly-Lys-Thr confers cell sensitivity to anticancer agents by inhibiting the binding of CAGE to GSK3β and reducing the expression of CyclinD1 ^[1].

HY-P4979

Cdc25A (80-93) (human)	Biochemical Assay Reagents	Cancer
Cdc25A (80-93) (human) is a polypeptide that controls the cell proliferation and tumorigenesis by a change in expression of proteins involved in cyclin D1 regulation and G1/S transition. Cdc25A (80-93) (human) can be used in cancer research ^[1].

HY-P11782

GTGKT	GSK-3 CDK Apoptosis	Cancer
GTGKT is a CAGE inhibitor. GTGKT binds to CAGE and blocks the binding of CAGE to GSK3β. GTGKT alters the localization of CAGE and inhibits the binding of CAGE to the promoter sequence of *Cyclin D1. GTGKT enhances the Apoptotic* effect of anticancer agents. GTGKT reduces the expression of *Cyclin D1*. GTGKT decreases the tumorigenic potential of melanoma and hepatocellular carcinoma cells ^[1].

製品番号	製品名	Target	研究分野	Image

HY-P991883

Metuzumab Licartin; Metuximab; Mehuzumab	Apoptosis CDK Caspase Bcl-2 Family	Cancer
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of *Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax* expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2]_.

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	Sf9 insect cells (1) E. coli (1)

製品番号	Compare	製品名	Species	Source	Image

HY-P701366

	CDK6-CCND1 Heterodimer Protein, Human (sf9) CDK6; CCND1; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D1; B-cell lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND1 Heterodimer protein, expressed by sf9 insect cells , with tag free.

HY-P72119

	CCND1 Protein, Human (His) AI327039; B cell leukemia 1; B-cell lymphoma 1 protein; BCL 1; BCL-1; BCL-1 oncogene; BCL1; BCL1 oncogene; ccnd1; CCND1/FSTL3 fusion gene; CCND1/FSTL3 fusion gene; included; CCND1/IGHG1 fusion gene; CCND1/IGLC1 fusion gene; CCND1_HUMAN; cD1; Cyl 1; D11S287E; G1/S specific cyclin D1; G1/S-specific cyclin-D1; PRAD1; PRAD1 oncogene; U21B31	Human	E. coli
	The CCND1 protein is a regulatory component of the cyclin D1-CDK4 complex that coordinates phosphorylation and RB family inhibition to regulate the G(1)/S transition. This promotes the dissociation of E2F from the RB/E2F complex and promotes the transcription of E2F target genes critical for G(1) phase progression. CCND1 Protein, Human (His) is the recombinant human-derived CCND1 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Product


Product	在庫あり - + カートに追加
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 在庫あり - + カートに追加お問い合わせ

製品番号	製品名	構造式

HY-152051S

Mabuterol-d9 hydrochloride

Mabuterol-d₉ (hydrochloride) is deuterium labeled Mabuterol (hydrochloride). Mabuterol hydrochloride is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol hydrochloride inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol hydrochloride suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB ^[1] .

HY-18981S

Decursin-d6

Decursin-d₆ ((+)-Decursin-d₆) is the deuterium labeled Decursin (HY-18981). Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities ^[1] .

Host:	Mouse (5) Rabbit (3)
Reactivity:	Human (8) Rat (3) Mouse (5)
Application:	IHC-P (7) ICC/IF (4) IP (3) WB (6) FC (4) ELISA (6)
Isotype:	IgG (3) IgG1 (4)
Conjugation:	Non-conjugated (8)
Clonality:	Polyclonal (1) Monoclonal (5) Recombinant (1)
Modification:	Unmodified (6)

製品番号	Compare	製品名	Application	Reactivity	Image

HY-P80098

	Cyclin D1/CCND1 Antibody (YA485) CCND1; BCL1; PRAD1; G1/S-specific cyclin-D1; B-cell lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
	Cyclin D1/CCND1 Antibody (YA485) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cyclin D1/CCND1.

HY-P85114

	Cyclin D1/CCND1 Antibody (YA4806) CCND1; BCL1; PRAD1; G1/S-specific cyclin-D1; B-cell lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	WB, ELISA	Human
	Cyclin D1/CCND1 Antibody (YA4806) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Cyclin D1/CCND1.

HY-P86563

	Cyclin D1/CCND1 Antibody (YA6255) CCND1; BCL1; PRAD1; G1/S-specific cyclin-D1; B-cell lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Cyclin D1/CCND1 Antibody (YA6255) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cyclin D1/CCND1.

HY-P80633

	Cyclin D1/CCND1 Antibody CCND1; BCL1; D11S287E; PRAD1; U21B31; Cyclin D1	WB, IHC-P, IP	Human, Mouse, Rat
	Cyclin D1/CCND1 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Cyclin D1/CCND1.

HY-P84204

	Cyclin D1/CCND1 Antibody (YA3901) BCL1; PRAD1; U21B31; D11S287E	WB, IHC-P, FC, ELISA	Human, Mouse
	Cyclin D1/CCND1 Antibody (YA3901) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cyclin D1/CCND1.

HY-P84203

	Cyclin D1/CCND1 Antibody (YA3900) BCL1; PRAD1; U21B31; D11S287E	IHC-P, ICC/IF, FC, ELISA	Human
	Cyclin D1/CCND1 Antibody (YA3900) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cyclin D1/CCND1.

HY-P84203A

	Cyclin D1/CCND1 Antibody (YA3900)(PBS only) BCL1; PRAD1; U21B31; D11S287E	IHC-P, ICC/IF, FC, ELISA	Human
	Cyclin D1/CCND1 Antibody (YA3900) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cyclin D1/CCND1.

HY-P84204A

	Cyclin D1/CCND1 Antibody (YA3901)(PBS only) BCL1; PRAD1; U21B31; D11S287E	WB, IHC-P, FC, ELISA	Human, Mouse
	Cyclin D1/CCND1 Antibody (YA3901) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cyclin D1/CCND1.

Compare Products


Products	在庫あり - + カートに追加
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 在庫あり - + カートに追加お問い合わせ

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: